Sales and Product Update

Genip

10/02/2026 07:00

RNS Number : 3014S

GenIP PLC

10 February 2026

 

 

 

 

10 February 2026

 

GenIP Plc

("GenIP" or the "Company")

 

Sales and Product Update

 

GenIP Plc, the AI-powered innovation intelligence and technology commercialisation company, is pleased to report continued momentum across corporate and academic markets, building on the operational progress detailed in its January Corporate Update and reflecting a broadening interest in the newer portfolio-based products Invention Prioritizer and Invention Validator.    

 

Corporate Clients

 

In line with the strategic drive to build the corporate customer base:

 

●    A Spanish innovation network serving c.12,000 businesses has adopted the Invention Prioritizer product for its portfolio management.

●    A US Intellectual Property strategy consultancy has engaged GenIP to support its inventor and innovation community. 

  

Academic Clients

 

A UK university has expanded its use of GenIP's products beyond the Invention Evaluator report, commissioning more in-depth, market-focused analysis to support decisions across their technology portfolio.

         

Discussions and proposals continue with Academic Institutes across Europe, LATAM, and the Middle East.     

 

These developments with new and existing customers demonstrate that GenIP's products are becoming embedded in the core decision making workflows of research organisations, directly shaping how they prioritise and allocate investment across their portfolios. This deeper integration strengthens GenIP's commercial proposition, supporting sustained price and margin expansion while locking in recurring revenue throughout the customer's investment and decision cycles.

 

Innovation Exchange Webinar Series

 

In January, GenIP launched its Innovation Exchange webinar series, showcasing how leading research institutes and organisations are rethinking technology commercialisation strategies. The first session demonstrated how KAUST (King Abdullah University of Science and Technology) manages its technology transfer operations and how they use GenIP's products. The session was well attended by over 40 organisations across four continents. It is planned that this series will provide monthly webinars delivering substantive discussions on how to systematically move new technologies to market. The next two sessions are already planned, involving Universities in Puerto Rico and Brazil. Initially free to attend, it is hoped to build this into a subscription series.

    

Panel Speaker at Industry Events  

 

GenIP will be a member of a Panel discussing "Beyond Incentives: Redefining the Value Proposition for Underserved Populations." at the Annual Meeting of AUTM (Association of University Technology Managers) in Seattle USA in February - the technology transfer industry's primary conference and exhibition in the Americas. This reflects the growing profile of the Company within the in technology transfer industry.    

    

Melissa Cruz, CEO of GenIP, commented:

"This update reflects a clear evolution in how organisations are engaging with GenIP. Repeat customers are expanding their use of our products, while new corporate clients are adopting higher-value, portfolio-level solutions as part of their ongoing decision-making processes.

With global R&D spending now approaching USD 3 trillion* per year, yet fewer than 20% of innovations ultimately reaching the market, research organisations are under increasing pressure to make faster, more disciplined portfolio decisions.

GenIP is addressing this challenge by embedding structured portfolio prioritisation into core innovation workflows, enabling more efficient capital allocation and accelerating the path from research to commercial outcomes. This is translating into growing international momentum across both academic and corporate markets."

*Source: World Intellectual Property Organization (WIPO), Global Innovation Index - End-of-Year Edition 2025.

    

For further information regarding GenIP, please visit www.genip.ai, or contact:

 

GenIP Plc
Melissa Cruz, CEO
Via Redchurch Communications
AlbR Capital Limited (Broker)
Colin Rowbury
Jon Belliss
Tel: +44 (0)20 7399 9427
cr@albrcapital.com
Jb@albrcapital.com
Redchurch Communications (Financial PR)
John Casey
genip@weareredchurch.com

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation consultancy at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

Service
Description
Value Proposition
Invention Intelligence Product Suite
AI-powered market intelligence reports assessing the commercial potential of emerging technologies
Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy
Talent and Executive Search Services
Executive search platform using machine learning and NLP to match innovation-driven organisations with commercialisation-ready leadership
De-risks scaling by aligning technical vision with proven executive capability

 

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

 

●    Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

●    Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRASSEFMUEMSEFE